1. Home
  2. REBN vs AKTX Comparison

REBN vs AKTX Comparison

Compare REBN & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reborn Coffee Inc.

REBN

Reborn Coffee Inc.

HOLD

Current Price

$1.65

Market Cap

8.7M

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.25

Market Cap

9.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REBN
AKTX
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.7M
9.1M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
REBN
AKTX
Price
$1.65
$0.25
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$2.53
AVG Volume (30 Days)
61.8K
306.2K
Earning Date
03-30-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,663,303.00
N/A
Revenue This Year
$335.98
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.09
N/A
52 Week Low
$1.37
$0.22
52 Week High
$8.30
$1.73

Technical Indicators

Market Signals
Indicator
REBN
AKTX
Relative Strength Index (RSI) 44.67 44.92
Support Level $1.63 $0.23
Resistance Level $1.99 $0.27
Average True Range (ATR) 0.13 0.02
MACD -0.02 0.00
Stochastic Oscillator 11.93 48.25

Price Performance

Historical Comparison
REBN
AKTX

About REBN Reborn Coffee Inc.

Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: